| Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia AC Rawstron, FL Bennett, SJM O'Connor, M Kwok, JAL Fenton, ... New England Journal of Medicine 359 (6), 575-583, 2008 | 793 | 2008 |
| ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells M Kwok, N Davies, A Agathanggelou, E Smith, C Oldreive, E Petermann, ... Blood, The Journal of the American Society of Hematology 127 (5), 582-595, 2016 | 286 | 2016 |
| Minimal residual disease is an independent predictor for 10-year survival in CLL M Kwok, AC Rawstron, A Varghese, PAS Evans, SJM O’Connor, ... Blood, The Journal of the American Society of Hematology 128 (24), 2770-2773, 2016 | 151 | 2016 |
| Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway M Kwok, N Davies, A Agathanggelou, E Smith, E Petermann, E Yates, ... The Lancet 385, S58, 2015 | 84 | 2015 |
| USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status A Agathanggelou, E Smith, NJ Davies, M Kwok, A Zlatanou, CE Oldreive, ... Blood, The Journal of the American Society of Hematology 130 (2), 156-166, 2017 | 77 | 2017 |
| Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells C Chuah, DJ Barnes, M Kwok, A Corbin, MWN Deininger, BJ Druker, ... Leukemia 19 (11), 1896-1904, 2005 | 75 | 2005 |
| Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia HM Parry, N Mirajkar, N Cutmore, J Zuo, H Long, M Kwok, C Oldrieve, ... Frontiers in immunology 10, 2832, 2019 | 41 | 2019 |
| Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL M Kwok, C Oldreive, AC Rawstron, A Goel, G Papatzikas, RE Jones, ... Blood, The Journal of the American Society of Hematology 135 (6), 411-428, 2020 | 29 | 2020 |
| Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy. M Kwok, AC Rawstron, A Varghese, P Hillmen Blood 114 (22), 540, 2009 | 22 | 2009 |
| Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts NJ Davies, M Kwok, C Gould, CE Oldreive, J Mao, H Parry, E Smith, ... Oncotarget 8 (27), 44749, 2017 | 18 | 2017 |
| Targeting the p53 pathway in CLL: State of the art and future perspectives M Kwok, A Agathanggelou, N Davies, T Stankovic Cancers 13 (18), 4681, 2021 | 17 | 2021 |
| Clonal evolution of high-risk chronic lymphocytic leukemia: A contemporary perspective M Kwok, CJ Wu Frontiers in oncology 11, 790004, 2021 | 15 | 2021 |
| Cancer and COVID-19: on the quest for effective vaccines M Kwok, EF Fritsch, CJ Wu Blood cancer discovery 2 (1), 13-18, 2021 | 6 | 2021 |
| Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia M Kwok, A Rawstron, A Varghese, P Evans, S O'Connor, C Doughty, ... The Lancet 383, S66, 2014 | 5 | 2014 |
| Synthetic lethality In CLL with DNA damage response defect by targeting ATR pathway T Stankovic, D Nicholas, M Kwok, E Smith, E Yates, A Agathanggelou, ... Blood 122 (21), 120, 2013 | 5 | 2013 |
| Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer M Kwok, T Stankovic Targeting Cell Survival Pathways to Enhance Response to Chemotherapy, 203-230, 2019 | 3 | 2019 |
| Ibrutinib: another string to its bow T Stankovic, M Kwok Blood, The Journal of the American Society of Hematology 137 (25), 3461-3462, 2021 | 2 | 2021 |
| Genetics in the era of targeted CLL therapy T Stankovic, M Kwok Blood, The Journal of the American Society of Hematology 135 (26), 2333-2334, 2020 | 2 | 2020 |
| Targeting Replication Stress in Sporadic Tumours M Kwok, T Stankovic DNA Repair and Replication, 329-340, 2018 | 2 | 2018 |
| ATR Inhibition Exacerbates Replication Stress in TP53 or ATM Deficient CLL Cells and Enhances Sensitivity to Chemotherapy and Targeted Therapy M Kwok, N Davies, A Agathanggelou, E Smith, E Petermann, E Yates, ... Blood 124 (21), 3340, 2014 | 2 | 2014 |
